Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306004 | 0.81 | TBXAS1 (0.50) | EPHX2PPARGTBXAS1LTB4RLTB4R2 | |
| SCHEMBL305027 | 0.81 | TBXAS1 (0.50) | EPHX2PPARGTBXAS1LTB4RLTB4R2 | |
| SCHEMBL875044 | 0.79 | BACE1 (0.39) | BACE1 | |
| SCHEMBL4603138 | 0.79 | BACE1 (0.51) | BACE1TBXAS1 | |
| SCHEMBL4603145 | 0.79 | BACE1 (0.51) | BACE1TBXAS1 | |
| SCHEMBL305026 | 0.77 | BACE1 (0.47) | BACE1TBXAS1 | |
| SCHEMBL28343924 | 0.75 | ALDH1A1 (0.35) | BACE1 | |
| SCHEMBL1564661 | 0.74 | HTT (0.44) | — | |
| SCHEMBL4822404 | 0.72 | PDCD1 (0.34) | BACE1 | |
| SCHEMBL7955217 | 0.72 | EPHX2 (0.41) | EPHX2PPARGTBXAS1ALOX5PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | BACE1 59/4885EPHX2 3473/4885PPARG 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.